3 ms·
I think the articles are similar to most articles on a "new" pharmaceutical. They overblow the benefits, misinterpret the underlying study, and just generally
by giantg2 5y ago
I think the articles are similar to most articles on a "new" pharmaceutical. They overblow the benefits, misinterpret the underlying study, and just generally want to seduce the reader.
In this case, the phase 1 trial found that psilocybin has a favorable safety profile in a small study, clearing it for larger studies to find rarer side-effects and evaluate efficacy as a treatment. That's basically it. They can't legitimately claim "psilocybin has no short- or long-term detrimental effects" in a study that small. But it's commonly done for this and other pharmaceuticals.